早期尿激酶静脉溶栓治疗急性心肌梗死68例临床观察

目的探讨早期激酶静脉溶栓治疗急性心肌梗死的临床疗效及安全性。方法将68例AMI患者采用早期使用尿激酶溶栓治疗静脉再通溶栓治疗,并与68例AMI患者的常规治疗作对照。观察溶栓治疗患者的再通情况及其溶栓后24小时内T波倒置对判定冠脉再通的意义。结果尿激酶观察组与对照组的冠脉再通率分别为66.2%和16.2%,两组再通率差异有统计学意义(P<0.05),发病至开始溶栓时间越短,再通率越高。结论早期尿激酶溶栓治疗可提高急性心肌梗死疗效,降低死亡率。ST-T改变和T波倒置具有判断闭塞冠脉的临床价值。

Clinical Observation of Early Intravenous Thrombolysis with Urokinase in Treating 68 Cases with Acute Myocardial Infarction

Objective To investigate the clinical efficacy and safety of the urokinase early intravenous thrombolytic in the treatment of acute myocardial infarction.Methods 68 cases of AMI patients with early use of intravenous thrombolytic therapy by urokinase thrombolytic therapy recanalization,and 68 cases of AMI patients with conventional treatment as control,were observed with thrombolytic therapy and its thrombolytic recanalization within 24 hours after T-wave inversion to determine the significance of coronary recanalization.Results Urokinase observation group and control group of coronary artery recanalization rates were 66.2% and 16.2% respectively;the recanalization rate had statistically significant difference(P <0.05) between the two groups.Incidence to the beginning of thrombolysis,the shorter the time,and then the higher rate of recanalization.Conclusion Early thrombolytic therapy with urokinase in acute myocardial infarction can improve efficacy,reduce mortality.ST-T changes and T wave inversion has the clinical value to determine coronary occlusion.